Zogenix Garners $20,000,000 Series B Financing

  • Feed Type
  • Date
    12/7/2009
  • Company Name
    Zogenix
  • Mailing Address
    12671 High Bluff Drive San Diego, CA 92130
  • Company Description
    Zogenix is a specialty pharmaceutical company whose goal is to uniquely enhance and differentiate medicines by incorporating innovative technologies in an effort to relieve suffering in people with CNS and pain disorders. Founded in 2006, the company currently has two proprietary product candidates in late-stage development. Our lead product candidate, SUMAVEL™ DOSEPRO™ (sumatriptan injection) needle-free delivery system, is a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan – the fastest acting migraine medicine – for the treatment of migraine and cluster headache. Our second product candidate, ZX002, is a novel, oral controlled-release formulation of hydrocodone for the treatment of chronic pain.
  • Website
    http://www.zogenix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The capital primarily will be used to fully support the launch of SUMAVEL(TM) DosePro(TM) (sumatriptan injection) needle-free delivery system, the company’s first product, that will launch in January 2010. Zogenix is also advancing its product pipeline and is actively engaged in efforts to out-license the unique, needle-free DosePro technology to other biopharmaceutical companies.
  • M&A Terms
  • Venture Investor
    Chicago Growth Partners

Trending on Xconomy